EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of an effective treatment for liver fibrosis based on a long acting easy to deliver TNF-α-derived peptide

Xiaowen Qiu, Xiaohua Wang, Xiaohuan Yuan, Mengxin Yao, Zhanpeng Sun, Zhihan Gao, Jiaru Zhang, Caiyun Xia, Ping Zhang, Linru Sun, Zhao Wang, Haifeng Liu

Pharmacological Research · 2025

DOI: 10.1016/j.phrs.2025.108010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2025. Verfasst von Xiaowen Qiu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang 157011, PR China; College of Life Scienc…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Liver Cirrhosis, Peptides. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Heilongjiang Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor necrosis factor α (TNF-α) is an attractive anti-liver fibrosis drug because of its cell apoptosis-inducing ability on activated hepatic stellate cells (HSCs) via TNF-α receptor 1 (TNFR1). However, the application of TNF-α has been limited by its short half-life, poor targeting capacity and promotion of cell proliferation via TNF-α receptor 2 (TNFR2). TNF-α-derived peptide, P16, specific induces cell apoptosis by its binding to TNFR1 but not TNFR2. Endogenous IgG-based controlled release is an ideal strategy for extending the serum half-life via FcRn-mediated recycling, and platelet-derived growth factor receptor β (PDGFRβ)-mediated endocytosis improves fibrotic liver-targeting potential because of its overexpression on activated HSCs. Herein, we designed a tridomain Z-IgBD-P16, by sequentially fusing a PDGFRβ-specific affibody ZPDGFRβ and two repeats of IgG-binding domain (IgBD) to the N-terminus of P16. ZPDGFRβ-mediated binding of Z-IgBD-P16 to PDGFRβ targeted activated HSCs in fibrotic liver. IgBD provided Z-IgBD-P16 with IgG binding and prolonged the circulatory half-life in blood. These two superiorities endowed Z-IgBD-P16 with the higher fibrotic liver uptake and stronger apoptosis-inducing activity in activated HSCs, resulting in the enhanced anti-liver fibrosis efficacy in vivo via the mitochondrial-dependent pathway. These findings suggest that Z-IgBD-P16 represents a promising targeted candidate for liver fibrosis treatment. Moreover, the application of dual strategies based on IgBD-mediated long-acting capacity and ZPDGFRβ-mediated targeting of PDGFRβ to design other functional peptide or protein can enhance the treatment efficacy of PDGFRβ-overexpressing other diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor-alphaLiver CirrhosisPeptidesAnimalsHumansHepatic Stellate CellsMaleReceptor, Platelet-Derived Growth Factor betaMice, Inbred C57BLMiceApoptosisLiver

Stichwörter der Autor:innen

ApoptosisDrug deliveryHepatic stellate cellsImmunoglobulinLiver fibrosisPlatelet-derived growth factor β receptor

Substanzen

Tumor Necrosis Factor-alphaReceptor, Platelet-Derived Growth Factor betaPeptides

Autor:innen und Institutionen

  • Heilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang 157011, PR China; College of Life Science, Mudanjiang Medical University, Mudanjiang 157011, PR China.
  • Laboratory of Pathogenic Microbiology and Immunology, Mudanjiang Medical University, Mudanjiang 157011, PR China; Department of Cell Biology, Mudanjiang Medical University, Mudanjiang 157011, PR China.
  • Heilongjiang Province Key Laboratory for Anti-fibrosis Biotherapy, Mudanjiang Medical University, Mudanjiang 157011, PR China.
  • College of Life Science, Mudanjiang Medical University, Mudanjiang 157011, PR China.
  • Department of Joint and Bone Tumor Surgical, the Second Hospital Affiliated to Wenzhou Medical University, Wenzhou 325035, PR China.
  • Department of Cell Biology, Mudanjiang Medical University, Mudanjiang 157011, PR China.

Förderung

  • Heilongjiang Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Qiu, X., Wang, X., Yuan, X., Yao, M., Sun, Z., Gao, Z., Zhang, J., Xia, C., Zhang, P., Sun, L., Wang, Z., & Liu, H. (2025). Identification of an effective treatment for liver fibrosis based on a long acting easy to deliver TNF-α-derived peptide. Pharmacological Research. https://doi.org/10.1016/j.phrs.2025.108010

Vancouver

Qiu X, Wang X, Yuan X, Yao M, Sun Z, Gao Z, et al. Identification of an effective treatment for liver fibrosis based on a long acting easy to deliver TNF-α-derived peptide. Pharmacological Research. 2025. doi:10.1016/j.phrs.2025.108010

BibTeX
@article{Qiu2025,
  author = {Qiu, Xiaowen and Wang, Xiaohua and Yuan, Xiaohuan and Yao, Mengxin and Sun, Zhanpeng and Gao, Zhihan and Zhang, Jiaru and Xia, Caiyun and Zhang, Ping and Sun, Linru and Wang, Zhao and Liu, Haifeng},
  title = {Identification of an effective treatment for liver fibrosis based on a long acting easy to deliver TNF-α-derived peptide},
  journal = {Pharmacological Research},
  year = {2025},
  doi = {10.1016/j.phrs.2025.108010}
}
Kostenlos starten →